StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.83−0.12 (-6.15%)

Close on Nov 19, 2026Market cap $7.41MP/E 0.0Yield –

Kyntra Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Kyntra Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$38.06M. For fiscal 2025 it was -$4.81M. The highest annual figure on record is $77.61M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.81M–
FY2024Dec 31, 2024-$138.27M–
FY2023Dec 31, 2023-$317.54M–
FY2022Dec 31, 2022-$149.67M–
FY2021Dec 31, 2021-$87.42M-212.6%
FY2020Dec 31, 2020$77.61M–
FY2019Dec 31, 2019-$84.47M–
FY2018Dec 31, 2018-$84.16M–
FY2017Dec 31, 2017-$75.01M-1381.0%
FY2016Dec 31, 2016$5.86M–
FY2015Dec 31, 2015-$20.55M-243.7%
FY2014Dec 31, 2014$14.30M-25.2%
FY2013Dec 31, 2013$19.11M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.99M-131.5%
Q1 FY2026Mar 31, 2026-$13.89M-613.8%
Q4 FY2025Dec 31, 2025-$18.33M–
Q3 FY2025Sep 30, 2025-$1.86M–
Q2 FY2025Jun 30, 2025$12.67M–
Q1 FY2025Mar 31, 2025$2.70M–
Q4 FY2024Dec 31, 2024-$30.61M–
Q3 FY2024Sep 30, 2024-$8.46M–
Q2 FY2024Jun 30, 2024-$39.88M–
Q1 FY2024Mar 31, 2024-$59.32M–
Q4 FY2023Dec 31, 2023-$18.57M–
Q3 FY2023Sep 30, 2023-$85.22M–
Q2 FY2023Jun 30, 2023-$111.56M–
Q1 FY2023Mar 31, 2023-$102.18M–
Q4 FY2022Dec 31, 2022-$52.85M–
Q3 FY2022Sep 30, 2022-$52.75M-223.6%
Q2 FY2022Jun 30, 2022-$33.97M–
Q1 FY2022Mar 31, 2022-$10.11M–
Q4 FY2021Dec 31, 2021-$56.36M–
Q3 FY2021Sep 30, 2021$42.68M–
Q2 FY2021Jun 30, 2021-$28.24M-119.0%
Q1 FY2021Mar 31, 2021-$45.50M–
Q4 FY2020Dec 31, 2020-$9.62M–
Q3 FY2020Sep 30, 2020-$1.77M–
Q2 FY2020Jun 30, 2020$148.94M–
Q1 FY2020Mar 31, 2020-$59.95M-372.5%
Q4 FY2019Dec 31, 2019-$46.80M–
Q3 FY2019Sep 30, 2019-$29.29M-512.5%
Q2 FY2019Jun 30, 2019-$30.38M–
Q1 FY2019Mar 31, 2019$22.00M–
Q4 FY2018Dec 31, 2018-$20.63M–
Q3 FY2018Sep 30, 2018$7.10M–
Q2 FY2018Jun 30, 2018-$36.83M–
Q1 FY2018Mar 31, 2018-$33.80M–
Q4 FY2017Dec 31, 2017-$4.69M–
Q3 FY2017Sep 30, 2017-$21.81M–
Q2 FY2017Jun 30, 2017-$20.73M–
Q1 FY2017Mar 31, 2017-$27.77M–
Q4 FY2016Dec 31, 2016-$18.69M–
Q3 FY2016Sep 30, 2016-$1.85M–

More Kyntra Bio figures

See a number that looks wrong?